Recordati Sets 3-Year Goals Driven By Organic Growth & M&A

Recordati Sets 3-Year Goals Driven By Organic Growth & M&A

By Karen Roman Recordati said it established its three-year financial targets for 2025-2027, with expected revenue of €3.0 to €3.2 billion for 2027 and EBITDA of €1.14 to €1.225 billion. The company’s strategy is driven by organic growth, its leadership,...

Araris Biotech Partners with Johnson & Johnson to Develop Cancer Therapies

Araris Biotech Partners with Johnson & Johnson to Develop Cancer Therapies

By Daniella Parra Araris Biotech AG  joined a research agreement with Johnson & Johnson’s Janssen Biotech to advance the development of next-generation antibody-drug conjugates (ADCs), they said. The partnership will leverage Araris’ proprietary AraLinQ technology, a one-step, enzymatic conjugation platform...

March Bio Starts Phase 2 Trial for Rare Blood Cancer

March Bio Starts Phase 2 Trial for Rare Blood Cancer

By Karen Roman March Biosciences said it started Phase 2 trial for MB-105, its CAR-T therapy for patients with relapsed or refractory CD5+ T-cell lymphoma. The test will take place at leading cancer centers across the country, with the first...

Nanox New Imaging System Receives FDA Clearance

Nanox New Imaging System Receives FDA Clearance

By Karen Roman Nano-X Imaging Ltd. (Nasdaq: NNOX) said its multi-source digital imaging system, Nanox.ARC X, received FDA 510(k) clearance for general use. The Nanox.ARC X has a simplified “plug and play” one-day installation feature and allows remote software upgrades,...

Vivani Medical Gives Data for Weight Loss Implant

Vivani Medical Gives Data for Weight Loss Implant

By Karen Roman Vivani Medical, Inc. (Nasdaq: VANI) announced positive data for NPM-139, its subdermal semaglutide implant for chronic weight management, with expected once or twice-yearly dosing. The results support the company’s NanoPortal implant for delivery of therapeutic molecules for...

Input your search keywords and press Enter.